Privia Health EVP granted 28,268 RSUs

Fargis Edward C reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Fargis Edward C reported acquisition or exercise transactions in this Form 4 filing.

Privia Health Group, Inc. executive vice president and general counsel Edward C. Fargis reported receiving a grant of 28,268 shares of common stock in the form of restricted stock units at no cash cost per share. These units were awarded under the 2021 Omnibus Incentive Plan.

The restricted stock units will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally contingent on continued service through each vesting date. Following this grant, Fargis directly holds 111,979 shares of common stock.

Insider Trade Summary

Grant/Award: 28,268 shares

Grant/Award 1 txn

Insider Fargis Edward C

Role EVP & General Counsel

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, $0.01 par value per share	28,268	$0.00	$0.00

Holdings After Transaction: Common Stock, $0.01 par value per share — 111,979 shares (Direct)

Footnotes (1)

1. F1. Reflects restricted stock units under the 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally subject to continued service throughout such dates.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Privia Health (PRVA) report for Edward C. Fargis?

Privia Health reported that EVP and general counsel Edward C. Fargis received 28,268 restricted stock units of common stock. The award was at no cash cost per share and represents equity-based compensation granted under the company’s 2021 Omnibus Incentive Plan.

How many Privia Health (PRVA) shares does Edward C. Fargis hold after this Form 4?

After the reported award, Edward C. Fargis directly holds 111,979 shares of Privia Health common stock. This figure includes the newly granted restricted stock units, which are subject to vesting over time based on his continued service with the company.

What type of equity award did Privia Health (PRVA) grant to Edward C. Fargis?

Edward C. Fargis received restricted stock units of Privia Health common stock. These units were granted under the 2021 Omnibus Incentive Plan and are compensation-related, not an open-market purchase, with vesting tied to future service milestones over several years.

What are the vesting terms of Edward C. Fargis’s Privia Health (PRVA) restricted stock units?

The restricted stock units will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date. Vesting is generally conditioned on Fargis continuing to serve the company through each of those vesting dates.

Was the Privia Health (PRVA) equity award to Edward C. Fargis an open-market share purchase?

No, the award was not an open-market purchase. It is a grant of 28,268 restricted stock units at a stated price of zero per share, reflecting equity compensation rather than a buy order executed in the public market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 05:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fargis Edward C

(Last) (First) (Middle)

PRIVIA HEALTH GROUP, INC.

950 N. GLEBE. RD., SUITE 700

(Street)

ARLINGTON VA 22203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Privia Health Group, Inc. [ PRVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value per share	03/10/2026		A		28,268(1)	A	$0	111,979	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects restricted stock units under the 2021 Omnibus Incentive Plan that will vest in substantially equal annual installments on the first, second and third anniversaries of the grant date, generally subject to continued service throughout such dates.

Remarks:

	/s/ Anita Beth Adams, as attorney-in-fact	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.